Trial Profile

A phase 2 study of YD-312 for treatment of diabetic retinopathy in USA

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 07 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imatinib (Primary)
Indications Diabetic macular oedema
Focus Therapeutic Use

Most Recent Events

07 Sep 2018 New trial record
27 Aug 2018 According to a YD Global Life Science media release, the US FDA has approved for the Phase 2 clinical trials of YD-312 for Diabetic retinopathy in Apr 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com